Browsed by
Month: April 2019

Dr. Aubrey de Grey Accelerates His Estimates – Article by Steve Hill

Dr. Aubrey de Grey Accelerates His Estimates – Article by Steve Hill

Steve Hill


Editor’s Note: In this article, Mr. Steve Hill highlights a recent webinar where Dr. Aubrey de Grey, the Biogerontology Advisor of the U.S. Transhumanist Party / Transhuman Party, revised his projections for the arrival of rejuvenation treatments in a more optimistic direction. This article was originally published by the Life Extension Advocacy Foundation (LEAF).

~ Gennady Stolyarov II, Chairman, United States Transhumanist Party / Transhuman Party, April 16, 2019


On January 28, 2019, we held a webinar with the SENS Research Foundation as part of a new ongoing series of research webinars. During the webinar, we asked Dr. Aubrey de Grey how close we might be to achieving robust mouse rejuvenation (RMR) and robust human rejuvenation, and his answer was somewhat surprising.

RMR is defined as reproducibly trebling the remaining lifespan of naturally long-lived (~3 years average lifespan) mice with therapies begun when they are already two years old.

Dr. de Grey now suggests that there is a 50/50 chance of achieving robust mouse rejuvenation within 3 years from now; recent interviews and conversation reveal that he’d adjusted this figure down from 5-6 years. He has also moved his estimation of this to arrive from around 20 years to 18 years for humans.

So, what is the basis for this advance in schedule? Dr. de Grey is more optimistic about how soon we might see these technologies arrive, as the level of crosstalk between damages appears to be higher than he originally anticipated a decade ago. This means that robust mouse and human rejuvenation may be easier than he previously believed.

We also asked Dr. de Grey which of the seven damages of aging was the most challenging to address. Originally, he thought solving cancer through OncoSENS methods was the biggest challenge in ending age-related diseases. However, intriguingly, he speaks about his enthusiasm for immunotherapy and how it may potentially solve the cancer issue and negate the need for Whole-body Interdiction of Lengthening of Telomeres (WILT), which was always considered a last-resort approach to shutting down cancer.

There are two main components of the WILT approach. The first is to delete telomerase-producing genes from as many cells as possible, as human cancers lengthen telomeres through one of two available pathways, and the second is to avoid the harmful consequences of our cells no longer having telomerase by periodically transplanting fresh stem cells, which have also had their telomerase-associated genes knocked out, to replace losses.

This approach has always been considered extreme, and Dr. de Grey has always acknowledged that this was the case. However, over a decade ago when Dr. de Grey and Michael Rae originally proposed this in the book Ending Aging, immunotherapy was simply not on the radar. Now, there are alternatives to WILT that show true potential and less need for radical solutions, and it is reassuring to see that Dr. de Grey is so enthusiastic about them.

He now suggests that MitoSENS is probably the most challenging to tackle of the seven types of damage in the SENS model of aging. This is no surprise given that DNA and mtDNA damage are highly complex issues to fix.

On that note, we asked Dr. Amutha Boominathan from the MitoSENS team which mitochondrial gene was their next target after they had successfully created nuclear copies of the ATP-6 and ATP-8 genes.

MitoSENS will be launching a new fundraising campaign on Lifespan.io later this year with the aim of raising funds to progress to more of the mitochondrial genes. This time, the aim will be to move the approach to an animal model and demonstrate how it could be used to correct mitochondrial defects.

Finally, if you are interested in getting involved directly with these webinars and joining the live audience, check out the Lifespan Heroes page.

About  Steve Hill

As a scientific writer and a devoted advocate of healthy longevity technologies, Steve has provided the community with multiple educational articles, interviews and podcasts, helping the general public to better understand aging and the means to modify its dynamics. His materials can be found at H+ Magazine, Longevity reporter, Psychology Today and Singularity Weblog. He is a co-author of the book “Aging Prevention for All” – a guide for the general public exploring evidence-based means to extend healthy life (in press).

About LIFE EXTENSION ADVOCACY FOUNDATION (LEAF)

In 2014, the Life Extension Advocacy Foundation was established as a 501(c)(3) non-profit organization dedicated to promoting increased healthy human lifespan through fiscally sponsoring longevity research projects and raising awareness regarding the societal benefits of life extension. In 2015 they launched Lifespan.io, the first nonprofit crowdfunding platform focused on the biomedical research of aging.

They believe that this will enable the general public to influence the pace of research directly. To date they have successfully supported four research projects aimed at investigating different processes of aging and developing therapies to treat age-related diseases.

The LEAF team organizes educational events, takes part in different public and scientific conferences, and actively engages with the public on social media in order to help disseminate this crucial information. They initiate public dialogue aimed at regulatory improvement in the fields related to rejuvenation biotechnology.

Finally, Rejuvenation is a Thing! – Fresh Interview with Aubrey de Grey by Ariel VA Feinerman

Finally, Rejuvenation is a Thing! – Fresh Interview with Aubrey de Grey by Ariel VA Feinerman

logo_bg

Ariel VA Feinerman
Aubrey de Grey


This interview was originally published here

Preface

What is ageing? We can define ageing as a process of accumulation of the damage which is just a side-effect of normal metabolism. While researchers still poorly understand how metabolic processes cause damage accumulation, and how accumulated damage causes pathology, the damage itself — the structural difference between old tissue and young tissue — is categorized and understood pretty well. By repairing damage and restoring the previous undamaged — young — state of an organism, we can really rejuvenate it! It sounds very promising, and so it is. And for some types of damage (for example, for senescent cells) it is already proved to work!

Today in our virtual studio, somewhere between cold, rainy Saint-Petersburg and warm, sunny Mountain View, we meet Aubrey de Grey, again! For those of you who are not familiar with him, here is a brief introduction.

Dr Aubrey de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations. In 2011, de Grey inherited roughly $16.5 million on the death of his mother. Of this he assigned $13 million to fund SENS research.

Note: If you have not read “Ending Aging” yet I suggest you to do it as soon as possible, and to be more comfortable with the ideas we are discussing below I highly recommend you to read short introduction to SENS research on their web page. Also if you are interested in recent news and up-to-date reviews about [anti]ageing and rejuvenation research the best place to look for is Fight Aging! blog. Finally, if you are an investor or just curious, I highly encourage you to take a look at Jim Mellon’s book “Juvenescence”.

Interview

Ariel Feinerman: Hello, Dr Aubrey de Grey!

Aubrey de Grey: Hello Ariel — thanks for the interview.

Ariel Feinerman: How do you feel 2018 year? Can you compare 2018 to 2017 or early years? What is changing?

Aubrey de Grey: 2018 was a fantastic year for rejuvenation biotechnology. The main thing that made it special was the explosive growth of the private-sector side of the field — the number of start-up companies, the number of investors, and the scale of investment. Two companies, AgeX Therapeutics and Unity Biotechnology, went public with nine-digit valuations, and a bunch of others are not far behind. Of course this has only been possible because of all the great progress that has been made in the actual science, but one can never predict when that slow, steady progress will reach “critical mass”.

Ariel Feinerman: In 2017 SENS RF have received about $7 million. What has been accomplished in 2018?

Aubrey de Grey: We received almost all of that money right around the end of 2017, in the form of four cryptocurrency donations of $1 million or more, totalling about $6.5 million. We of course realised that this was a one-off windfall, so we didn’t spend it all at once! The main things we have done are to start a major new project at Albert Einstein College of Medicine, focused on stem cell therapy for Alzheimer’s, and to broaden our education initiative to include more senior people. See our website and newsletters for details.

Ariel Feinerman: What breakthroughs of 2018 can you name as the most important by your choice?

Aubrey de Grey: On the science side, well, regarding our funded work I guess I would choose our progress in getting mitochondrial genes to work when relocated to the nucleus. We published a groundbreaking progress report at the end of 2016, but to be honest I was not at all sure that we would be able to build quickly on it. I’m delighted to say that my caution was misplaced, and that we’ve continued to make great advances. The details will be submitted for publication very soon.

Ariel Feinerman: You say that many of rejuvenating therapies will work in clinical trials within five years. Giving that many of them are already working in clinical trials or even in the clinic (like immunotherapiescell and gene therapies) do you mean the first — maybe incomplete — rejuvenation panel, when you speak of early 2020?

Aubrey de Grey: Yes, basically. SENS is a divide-and-conquer approach, so we can view it in three overlapping phases. The first phase is to get the basic concept accepted and moving. The second phase is to get the most challenging components moving. And the third phase is to combine the components. Phase 1 is pretty much done, as you say. Phase 2 is beginning, but it’s at an early stage. Phase 3 will probably not even properly begin for a few more years. That’s why I still think we only have about a 50% chance of getting to longevity escape velocity by 2035 or so.

Ariel Feinerman: Even now many investors are fearful of real regenerative medicine approaches. For example pharmacological companies which use small molecules, like Unity Biotechnology, received more than $300 million, in much more favour than real bioengineering companies like Oisin Biotechnologies, received less than $4 million, even though the biological approach is much more powerful, cheap, effective and safe! Why is this so in your opinion, and when can we see the shift?

Aubrey de Grey: I don’t see a problem there. The big change in mindset that was needed has already occurred: rejuvenation is a thing. It’s natural that small-molecule approaches to rejuvenation will lead the way, because that’s what pharma already knows how to do. Often, that approach will in due course be overtaken by more sophisticated approaches. Sometimes the small molecules will actually work well! It’s all good.

Ariel Feinerman: Do you agree that the small-molecule approach is generally the wrong way in the future rejuvenation therapies? Because they have many flaws — especially their main mechanism via interference with human metabolism. Unlike them SENS bioengineering therapies are designed to be metabolically inert — because they just eliminate the key damage, they do not need to interfere with metabolism, so it is much easier than usual to avoid side effects and interactions with other therapies. They just eliminate the key damage, which means they are easier to develop and test — and much safer.

Aubrey de Grey: Ah, no, that’s too simplistic. It’s not true that small molecules always just “mess with metabolism” whereas genetic and enzymatic approaches eliminate damage. Small molecules that selectively kill senescent cells are absolutely an example of SENS-esque damage repair; the only thing against them is that it may be more difficult to eliminate side-effects, but that’s not because of their mode of action, it’s because of an additional action.

Ariel Feinerman: In recent years many countries gave the green light for regenerative medicine. Fast-track approval in Japan, for example, allows for emerging treatments to be used so long as they have been proven safe. The similar approach works in Russia. What about the EU or USA?

Aubrey de Grey: There’s definitely a long way to go, but the regulatory situation in the West is moving in the right direction. The TAME trial has led the way in articulating an approvable endpoint for clinical trials that is ageing in all but name, and the WHO has found a very well-judged way to incorporate ageing into its classification.

Ariel Feinerman: Do you think of working with USA Army? As far as we know they conduct research on regeneration and are very interested in keeping soldiers healthier for longer. And they have much money!

Aubrey de Grey: The Department of Defense in the USA has certainly funded a lot of high-impact regenerative medicine research for many years. I’m sure they will continue to do so.

Ariel Feinerman: Is any progress in the OncoSENS programme? Have you found any ALT genes? Is any ongoing research in WILT?

Aubrey de Grey: No — in the end that program was not successful enough to continue with, so we stopped it. There is now more interest in ALT in other labs than there was, though, so I’m hopeful that progress will be made. But also, one reason why I felt that it was OK to stop was that cancer immunotherapy is doing so well now. I think there is a significant chance that we won’t need WILT after all, because we will really truly defeat cancer using the immune system.

Ariel Feinerman: Spiegel Lab has recently published an abstract where they say they have found 3 enzymes capable of breaking glucosepane. Very exiting info! When can we hear more on their research? Revel LLC is a very secretive company.

Aubrey de Grey: They aren’t really being secretive, they are just setting up.

Ariel Feinerman: When can we see the first clinical trial of glucosepane breaker therapy?

Aubrey de Grey: I think two years is a reasonable estimate, but that’s a guess.

Ariel Feinerman: What do you think of the Open Source approach in rejuvenation biotechnology? The computer revolution in the early 2000s has taken place only because Open Source caused an explosion in software engineering!

We have many examples when Big Pharma buys a small company which has patents on technology and then cancels all research. In the Open Source approach you cannot “close” any technology, while everyone can contribute, making protocol better and everyone can use that without any licence fee! Anyway, there are countries where you cannot protect your patents. Maybe it will be better to make technology open from the beginning?

Famous biohacker Josiah Zayner said: “In the gene therapy world most treatments are easy to replicate or pirate because you can reverse engineer the DNA from scientific papers or patents. Same exact treatment, same purity and quality I could give to someone rejected from the clinical trial. The cost? Hundreds or a few thousand dollars at most. Same deal with immunotherapy.”

Aubrey de Grey: I think you’ve pretty much answered your own question with that quote. The technologies that will drive rejuvenation are not so easy to suppress.

Ariel Feinerman: Is the SENS RF going to begin new research programmes in 2019?

Aubrey de Grey: Sure! But we are still deciding which ones. We expect that our conference in Berlin (Undoing Aging, March 28–30) will bring some new opportunities to our attention.

Ariel Feinerman: What are your plans for 2019?

Aubrey de Grey: I’d like to say less travelling, but that doesn’t seem very likely at this point. Really my goal is just to keep on keeping on — to do all I can to maintain the growth of the field and the emerging industry.

Ariel Feinerman: Thank you very much for your answers, hope to see you again!

Aubrey de Grey: My pleasure!

Ariel VA Feinerman is a researcher, author, and photographer, who believes that people should not die from diseases and ageing, and whose main goal is to improve human health and achieve immortality. If you like Ariel’s work, any help would be appreciated via PayPal: arielfeinerman@gmail.com.

U.S. Transhumanist Party / Transhuman Party Call for 2020 Presidential Candidates and Outline of 2019 Endorsement and Primary Process

U.S. Transhumanist Party / Transhuman Party Call for 2020 Presidential Candidates and Outline of 2019 Endorsement and Primary Process

Gennady Stolyarov II


The United States Transhumanist Party / Transhuman Party (USTP) issues its call for candidates wishing to run for President of the United States in the 2020 elections and seeking an endorsement from the USTP. Candidates are encouraged to officially announce their intentions via this form and then spread awareness of the USTP, its forthcoming debate and primary process, and possibilities for individuals to sign up for free membership in the USTP in time to participate as voters in this process.

Because of the formidable hurdles to political-party ballot access on the State level, the candidates seeking the USTP’s endorsement would need to officially run as independent candidates. However, if those candidates qualify for inclusion on their States’ ballots, then, in approximately half of the jurisdictions in the United States, it would be possible to use a “political party designation” of “Transhumanist Party” to accompany the candidate’s name on the ballot.

Endorsement and Electronic Primary Process – Anticipated Timeline

The following timeline is approximate and subject to change as circumstances may necessitate. However, it is intended to provide an overarching impression of the sequence and desirable speed of steps for reaching an endorsement of a candidate for President of the United States.

– April 5, 2019 – June 30, 2019: Candidates declare their intention to seek the USTP Presidential endorsement and begin to campaign through channels of their choosing (online and/or in person) to attract supporters and spread awareness of their messages.

May 2019: The Transhumanism Handbook (edited by Newton Lee) is expected to be released. It is hoped that candidates will read this book (or significant portions thereof) and reference the ideas therein as part of their public outreach and campaign-related discussions.

June 30, 2019: First Transhumanist Presidential Debate (Virtual)

July 1 – August 3, 2019: Candidates continue to campaign; the USTP will introduce structured questions on various issues of interest for the candidates to respond to in writing. The candidates’ answers will be spread by the USTP, which will have the effect of further raising awareness of the candidates and their stances.

August 3, 2019: Second Transhumanist Presidential Debate (Virtual)

August 3-10, 2019: Final week for candidates to campaign prior to the electronic primary.

August 11-17, 2019: Electronic ranked-preference primary (7-day voting period, simultaneous for all USTP members).

August 18-24, 2019: Votes from the electronic primary are tabulated and released. The candidate winning the USTP endorsement is announced simultaneously with the release of the results.

August 24, 2019 – November 3, 2020: The candidate winning the USTP endorsement continues to campaign until Election Day 2020. The other candidates may seek the USTP’s endorsement for other federal, state, or local offices.

Early October 2019: Potential for the candidate winning the USTP endorsement to deliver an official acceptance speech in a venue with a large number of attendees.

U.S. Presidential Candidate Qualifications and Expectations

Qualifications Pursuant to the United States Constitution

Pursuant to Article 2, Section 1, of the United States Constitution, to be eligible to become President of the United States, the candidate must:

(1) Be at least 35 years old as of January 20, 2021 (i.e., born on or before January 20, 1986);

(2) Be a natural-born citizen of the United States; and

(3) Have been a resident of the United States for at least 14 years.

The USTP considers the existence of the above restrictions unfortunate, as they could disqualify many otherwise fine candidates. However, in the absence of a Constitutional Amendment, they are insurmountable during the 2020 election season.

Expectations of the Candidate from the U.S. Transhumanist Party / Transhuman Party

(4) If officially endorsed, the candidate must commit to running for office until Election Day 2020 (November 3, 2020). During the time prior to Election Day 2020, the candidate shall not concede to or endorse another candidate from another political party. The candidate also shall not run on behalf of any other political party.

(5) Although the candidate is not obligated to either raise or spend funds, if the candidate does choose to fundraise, the candidate must agree to perform any such fundraising for the candidate’s campaign independently of the U.S. Transhumanist Party / Transhuman Party. Furthermore, any campaign committee and/or bank account established by or on behalf of the candidate must be organizationally separate from the USTP. The USTP will spread information and raise public awareness about the candidate, but the USTP is a non-monetary organization and so cannot collect or disburse funds directly. The candidate must also agree to independently comply with all campaign-finance laws and report campaign contributions and expenses in the manner required pursuant to all applicable state and federal laws. The candidate must agree that responsibility for such compliance is solely on the part of the candidate, and that, as a non-monetary organization which does not finance campaigns, the USTP has no obligation nor legal liability in regard to such compliance. (The USTP may, however, at times assist the candidate by providing relevant information, as long as such assistance is understood to be non-obligatory in nature.)

(6) The candidate must agree to participate in the USTP Endorsement and Electronic Primary process as set forth herein and to respect the outcome of that process, no matter whether or not the candidate is ultimately endorsed to run for the office of President of the United States.

(7) The candidate should be in agreement with the USTP Core Ideals:

Ideal 1. The Transhumanist Party supports significant life extension achieved through the progress of science and technology.

Ideal 2. The Transhumanist Party supports a cultural, societal, and political atmosphere informed and animated by reason, science, and secular values.

Ideal 3. The Transhumanist Party supports efforts to use science, technology, and rational discourse to reduce and eliminate various existential risks to the human species.

(8) The candidate should have significant areas of alignment with the USTP Platform. While complete agreement with all positions therein is not required, and diversity of perspectives is encouraged, it should be possible for the public to clearly perceive the candidate as being closer to the USTP Platform than any given non-USTP-endorsed candidate – for instance, a Democratic, Republican, Libertarian, or Green candidate – would be.

(9) The candidate must agree to work collaboratively with the USTP during the campaign season and not to disparage the USTP as well as not to work contrary to the interests and goals of the USTP during that time.

(10) If officially endorsed, and if the candidate raises $5,000 or more in contributions or incurs $5,000 or more in expenditures, the candidate must agree to register as an independent candidate for President with the Federal Election Commission (FEC). Guidance pertaining to this process can be found on the FEC website here or in video form here. However, nothing obligates the candidate to either raise or spend $5,000 or more; any fundraising is at the candidate’s discretion.

For any questions, please e-mail Gennady Stolyarov II, Chairman of the USTP, here.

You can also complete the embedded form below to express your interest in becoming a U.S. Presidential candidate who would participate in the USTP Endorsement and Electronic Primary Process:

The 2020 Undoing Aging Conference Will Take Place May 21 to 23 in Berlin, Germany – Announcement by Undoing Aging

The 2020 Undoing Aging Conference Will Take Place May 21 to 23 in Berlin, Germany – Announcement by Undoing Aging

Undoing Aging


Editor’s Note: The U.S. Transhumanist Party features this announcement by the Undoing Aging Conference, a joint project between the SENS Foundation and the Forever Healthy Foundation,  originally published on their site on April 2, 2019.  The Undoing Aging Conference is focused on the cellular and molecular repair of age-related damage as the basis of therapies to bring aging under full medical control. Undoing Aging 2020 will once again bring together scientists and startups from around the globe, all pioneers in their respective fields, who are leading the charge in maintaining and restoring full health in old age. Such research is supported by the U.S. Transhumanist Party as part of our policy goals.

~ Brent Reitze, Applicant for Director of Publication, United States Transhumanist Party, April 4, 2019


April 2, 2019  Mountain View, California / Berlin, Germany

After the incredible success of the 2019 Undoing Aging Conference, SENS Research Foundation and Forever Healthy Foundation are pleased to announce Undoing Aging 2020, which will take place on May 21 – 23. As UA2019 was sold out with nearly 500 participants from over 30 countries, Undoing Aging 2020 will be moving to a larger venue.

Picture

The Undoing Aging Conference is focused on the cellular and molecular repair of age-related damage as the basis of therapies to bring aging under full medical control.  Among the 40 brilliant speakers at Undoing Aging 2019, there were giants in regenerative medicine such as: Dr. Nir Barzilai, Dr. Jerry Shay, Dr. Evan Snyder, Dr. Judith Campisi, and many more. Undoing Aging 2020 will once again bring together scientists and startups from around the globe, all pioneers in their respective fields, who are leading the charge in maintaining and restoring full health in old age. To accommodate the exciting growth of the emerging rejuvenation biotechnology industry, Undoing Aging 2020 will add a dedicated forum and exhibition space for rejuvenation biotech companies to present themselves to prospective investors and industry partners.

Additionally, the 2020 conference will add a special “Rejuvenation Now” session highlighting the first generation of human rejuvenation therapies that are either currently in clinical trials or are available today.

Undoing Aging 2020 is not only open to the scientific community, but also welcomes startups, investors, the general media, and all interested members of the broader rejuvenation movement. The conference will feature a student poster session showing the work of innovative undergraduate and graduate students in the field of damage repair.

“The accelerating rate of progress in rejuvenation research is now unmistakeable at all levels: publications, transfer into rapidly-funded startup companies, and even into the clinic. One marker of this is the worldwide proliferation of conferences focused on it. But I have no doubt that Undoing Aging will maintain its pre-eminence among them, with its strong focus on the most cutting-edge science, its long history dating back to my first Cambridge conference in 2003, and above all its steadfast support from Forever Healthy,” said Dr. Aubrey de Grey, CSO of SENS Research Foundation.

“We are very excited to work with SENS on Undoing Aging,” stated Michael Greve, founder, and CEO of the Forever Healthy Foundation. “Forever Healthy has two key goals for this conference: To support the remarkable scientific community and the rejuvenation biotechnology startups already working on repair of age-related damage and to create an unique opportunity to experience that bringing aging under complete, genuine medical control is realistic, achievable, and, indeed, beginning to happen.“


About Forever Healthy Foundation
Forever Healthy is a private, non-profit initiative with the mission to enable people to vastly extend their healthy lifespan and be part of the first generation to cure aging.

Thru its ‘Rejuvenation Now‘ and ‘Maximizing Health‘ initiatives, Forever Healthy seeks to continuously identify and evaluate new rejuvenation therapies on risks, benefits, and potential application and to harness the enormous wealth of the world’s cutting-edge medical knowledge to empower informed decisions about health and well-being.

In addition, Forever Healthy supports the development of rejuvenation therapies that undo the damage of aging by funding basic research, bringing together the world’s leading scientists at the Undoing Aging conference and supporting startups that work on actual therapies for human use. For more information, please visit forever-healthy.org

About SENS Research Foundation
SENS Research Foundation is a 501(c) nonprofit that works to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging. The foundation is focused on a damage-repair paradigm for treating the diseases of aging, which it advances through scientific research, advocacy, and education.

SENS Research Foundation supports research projects at universities and institutes around the world with the goal of curing such age-related diseases as heart disease, cancer, and Alzheimer’s disease. Educating the public and training researchers to support a growing regenerative medicine field are also significant endeavors of the organization that are being accomplished through advocacy campaigns and educational programs. For more information, please visit sens.org

To stay updated on Undoing Aging, you can follow their facebook page.

Announcing the Longevity Book Club for Lifespan Heroes – Announcement by Javier Noris

Announcing the Longevity Book Club for Lifespan Heroes – Announcement by Javier Noris

Javier Noris


Editor’s Note: The U.S. Transhumanist Party features this announcement by our cohorts at the Life Extension Advocacy Foundation, originally published on their site on March 19, 2019.  The program helps bring attention to published works promoting the mission of ending age-related diseases, a mission the U.S. Transhumanist Party supports as part of our policy goals.

~ Brent Reitze, Applicant for Director of Publication, United States Transhumanist Party, April 2, 2019


As mentioned in some recent articles, we are increasing our efforts to reward our loyal and invaluable monthly patrons that support us as Lifespan Heroes. We previously mentioned a brand-new, exclusive webinar series for Lifespan Heroes, and we want to take this opportunity to also announce another brand-new initiative that will commence in April.

Introducing the Longevity Book Club for Lifespan Heroes

As special thanks to our Lifespan Hero patrons, we are pleased to announce the launch of our new Longevity Book Club, where you can join other longevity enthusiasts in reading the most interesting works that relate to our mission of ending age-related diseases. You will also get the opportunity to listen to discussion panels and take part in Q&A sessions that are focused on books that touch on these important scientific, philosophical, moral and futuristic longevity topics. This is the ideal place to meet like-minded longevity enthusiasts who are working on building their knowledge on longevity and all of the implications that come with ending age-related diseases.

Our first book circle will be reading Homo Deus: A Brief History of Tomorrow by Yuval Noah Harari, a New York Times best-selling author.

Here is a brief synopsis of the book:

Yuval Noah Harari, author of the critically-acclaimed New York Times bestseller and international phenomenon Sapiens, returns with an equally original, compelling, and provocative book, turning his focus toward humanity’s future, and our quest to upgrade humans into gods.

Over the past century, humankind has managed to do the impossible and rein in famine, plague, and war. This may seem hard to accept, but, as Harari explains in his trademark style—thorough, yet riveting—famine, plague and war have been transformed from incomprehensible and uncontrollable forces of nature into manageable challenges. For the first time ever, more people die from eating too much than from eating too little; more people die from old age than from infectious diseases; and more people commit suicide than are killed by soldiers, terrorists and criminals put together. The average American is a thousand times more likely to die from binging at McDonalds than from being blown up by Al Qaeda.

What then will replace famine, plague, and war at the top of the human agenda? As the self-made gods of planet earth, what destinies will we set ourselves, and which quests will we undertake? Homo Deus explores the projects, dreams and nightmares that will shape the twenty-first century—from overcoming death to creating artificial life. It asks the fundamental questions: Where do we go from here? And how will we protect this fragile world from our own destructive powers? This is the next stage of evolution. This is Homo Deus.

With the same insight and clarity that made Sapiens an international hit and a New York Times bestseller, Harari maps out our future.

We feel this is a good book to get started with, as it’s written in a user-friendly style that can appeal to a broad audience and touches on many topics that are directly or indirectly related to our mission of ending age-related disease. As we progress as a group, we will shift into different categories, including philosophy, genetics, biochemistry, ethics, and many more topics that are of interest to our mission and book club members.

As a Hero, you will have the opportunity to join us for the first of many book discussions and have the opportunity to learn about the fascinating knowledge that these authors have to share with us as well as the deconstructed meanings behind the books as seen by our book club members. We’ll email the connection instructions to our Heroes soon, so please check your inbox for our announcement.

Calling all the Heroes

This year, our plan is to reach out to an even wider audience and engage with them about the need to end age-related diseases. We aim to hire another team member so that we can cover more news stories, buy new equipment, produce more films with popular Youtube channels, launch a two-day conference in NYC, and do more online shows, including this new webinar series.

However, to do this, we need your help.

We are very grateful for the support of our monthly patrons, the Lifespan Heroes, and we are asking you to consider joining them today in order to help us achieve our ambitious goals for 2019.

By becoming a Lifespan Hero, you become a monthly patron and can change or halt your contributions at any time. In return for your support, you get access to the Heroes’ private Discord channel, enjoy discounts on our event tickets, get early access to conference videos and live access to webinars, and receive regular reports on our progress and future plans.

Please consider becoming a Lifespan Hero today. We look forward to seeing you at the MitoSENS webinar and our Longevity Book Club meetings.

U.S. Transhumanist Party / Transhuman Party General Discussion Thread for the Second Quarter of 2019

U.S. Transhumanist Party / Transhuman Party General Discussion Thread for the Second Quarter of 2019

logo_bg


The purpose of this post is to facilitate member comments pertaining to transhumanism and the U.S. Transhumanist Party, which might not specifically fit the subjects of any other post or article on the U.S. Transhumanist Party website. This is the place for members to offer suggestions or converse about any areas of emerging technologies and their political, moral, societal, cultural, and esthetic implications. The general discussion thread is also an ideal location to suggest or propose platform planks that may be considered for future platform voting, and/or bring our attention to emerging legislative and societal developments that may affect the course and impact of emerging technologies.

The U.S. Transhumanist Party will endeavor to open one of these general comment threads per quarter. This comment thread pertains to the months of April, May, and June 2019.

Type in your comments below. Please note that, to protect against spambots, the first comment by any individual will be moderated. After passing moderation, a civil commenter should be able to post comments without future moderation – although we cannot guarantee that the technical aspect of this functionality will work as intended 100% of the time.